Skip to content

USCB Financial Holdings, Inc. USCB Options canceled (in dollars per share)

Options canceled (in dollars per share) at other companies

Ondas, Inc.
 logo
Ondas, Inc. ONDS
$5.42+274%
Xylem logo
XylemXYL
$127.87+13.3%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$15.04
Lesaka Technologies, Inc. logo
Lesaka Technologies, Inc.LSAK
$11.23+184%
USCB Financial Holdings, Inc. logo
USCB Financial Holdings, Inc.USCB
$0-100%
Avanos Medical logo
Avanos MedicalAVNS
$31.83-14.8%

Other financials

Income statement

See full
Revenue$26.2M+14.7%
Net income$9.4M+22.1%
EPS (diluted)$0.51+34.2%

Balance sheet

See full
Cash & equivalents$79.0M-19.4%
Total debt$4.8M-38.3%
Total equity$223.2M-0.8%
Total assets$2.8B+6.3%

Cash flow

See full
Operating cash flow$15.3M+4.4%
CapEx$320.0K+596%
Free cash flow$15.0M+2.6%

Valuation

See full
Market cap$363.27M+13.5%
Enterprise value$289.06M+25.8%
P/E13.1×+1.5×
P/S3.9×+0.2×

Profitability

See full
Net margin29.7%-1.8pp
FCF margin55.3%

Returns & leverage

See full
Return on equity12.4%-0.8pp
Debt / equity0.0×

Where this comes from

Reported directly by USCB Financial Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.

The official record: USCB Financial Holdings, Inc.’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about USCB Financial Holdings, Inc.'s options canceled (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is USCB Financial Holdings, Inc.'s options canceled (in dollars per share)?
USCB Financial Holdings, Inc. (USCB) reported options canceled (in dollars per share) of $0 in Q4 2025.
What does options canceled (in dollars per share) mean?
Indicates the weighted average exercise price or value per share associated with forfeited share-based compensation awards. This metric helps investors assess the potential impact of forfeited equity grants on the company's overall share-based compensation expense and dilution profile. It serves as a indicator of the value of unvested equity that did not result in share issuance.